[Progress in diagnosis and therapy: Hypercalcemia due to primary hyperparathyroidism].
Sugimoto
Toshitsugu
T
D019386:Alendronate / Q000008:administration & dosage; D015415:Biomarkers / Q000032:analysis; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002118:Calcium / Q000627:therapeutic use; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging; D006801:Humans; D006934:Hypercalcemia / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D049950:Hyperparathyroidism, Primary / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D010281:Parathyroid Hormone / Q000032:analysis; D016105:Parathyroidectomy; D011110:Polymorphism, Genetic; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D044169:Receptors, Calcium-Sensing / Q000235:genetics / Q000502:physiology; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D020845:Selective Estrogen Receptor Modulators; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; D002118:Calcium; D019386:Alendronate